Qiagen (NYSE:QGEN) Reaches New 52-Week Low – Here’s Why

Shares of Qiagen N.V. (NYSE:QGEN) reached a new 52-week low on Thursday . The company traded as low as $38.19 and last traded at $38.0610, with a volume of 419640 shares trading hands. The stock had previously closed at $39.97.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Friday, March 13th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a research report on Thursday, February 5th. Finally, Barclays set a $44.00 price objective on shares of Qiagen and gave the company an “equal weight” rating in a research report on Tuesday, April 14th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and a consensus target price of $53.64.

Qiagen Stock Performance

The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average of $43.41 and a 200-day moving average of $47.32. The firm has a market capitalization of $7.77 billion, a P/E ratio of 18.70, a P/E/G ratio of 2.08 and a beta of 0.79.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. During the same quarter in the prior year, the firm posted $0.61 EPS. The business’s revenue was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.5 EPS for the current year.

Institutional Trading of Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. United Services Automobile Association acquired a new stake in Qiagen in the 1st quarter valued at about $239,000. Prudential Financial Inc. lifted its position in Qiagen by 74.9% during the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock worth $426,000 after acquiring an additional 3,799 shares during the last quarter. Invesco Ltd. lifted its position in Qiagen by 123.7% during the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after acquiring an additional 556,387 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in Qiagen during the second quarter worth approximately $3,639,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.